FHMLS IX, L.L.C. 4
4 · Passage BIO, Inc. · Filed Mar 3, 2020
Insider Transaction Report
Form 4
Frazier Life Sciences IX, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-03-03+2,977,242→ 2,977,242 total - Conversion
Series A-1 Preferred Stock
2020-03-03−2,977,242→ 0 total→ Common Stock (2,977,242 underlying) - Conversion
Series A-2 Preferred Stock
2020-03-03−1,049,175→ 0 total→ Common Stock (1,049,175 underlying) - Conversion
Common Stock
2020-03-03+1,049,175→ 4,026,417 total - Conversion
Common Stock
2020-03-03+432,802→ 4,459,219 total - Purchase
Common Stock
2020-03-03$18.00/sh+550,000$9,900,000→ 5,009,219 total - Conversion
Series B Preferred Stock
2020-03-03−432,802→ 0 total→ Common Stock (432,802 underlying)
Footnotes (2)
- [F1]Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020.
- [F2]The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.